Domicilium Real Estate Fund III LP - 27 May 2026 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Reporting relationship: 10%+ Owner
Issuer ticker: ELOX
Reported as of: 27 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 10:44:56 UTC
Prior SEC filing: 04 May 2026
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner

Key filing fact

Domicilium Real Estate Fund III LP filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 05 Jun 2026.

Key facts

This page summarizes Domicilium Real Estate Fund III LP's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 10:44.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001945896 Primary reporting owner

Domicilium Real Estate Fund III LP

Relationship: 10%+ Owner
Address: 535 S. KIMBALL AVE, SUITE 140, SOUTHLAKE
Signature: Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELOX transaction

Common Stock, $0.01 par value per share

Other

Transaction value
Shares: -113,636
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 May 2026
Ownership: Direct
Footnotes: F1, F2, F3

ELOX holding

Common Stock, $0.01 par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 14,285
Date: 27 May 2026
Ownership: See footnote
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Pre-funded Warrant

Other

Transaction value
Shares: +113,636
Change %: +91%
Price
Shares after: 238,422
Date: 27 May 2026
Ownership: Direct
Underlying class: Common Stock, $0.01 par value per share
Underlying amount: 113,636
Exercise price
Footnotes: F1, F2, F3, F5

ELOX holding Derivative

Pre-funded Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,894,707
Date: 27 May 2026
Ownership: See footnote
Underlying class: Common Stock, $0.01 par value per share
Underlying amount: 0
Exercise price
Footnotes: F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Domicilium Real Estate Fund III LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants"), Domicilium Real Estate Fund III LP (the "Fund"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer.

Footnote F2

These securities reflect a 11 for 1 reverse stock split effective May 29, 2026.

Footnote F3

The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner.

Footnote F4

The securities are owned by various entities and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to such entities and (ii) Daniel Simon, the managing member of Domicilium.

Footnote F5

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

SEC remarks

Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.